The award will be granted quarterly throughout 2026 and is open to researchers worldwide working in the field of rare diseases. Its goal is to enable advanced analysis within some of biomedicine’s most complex and understudied areas.

“Research in rare diseases is driven by urgent clinical needs but is often limited by a lack of access to the right tools,” says Danuta Gawel, Chief Research & Development Officer at Mavatar. “With this initiative, we aim to empower scientists working in resource-constrained environments with scalable, data-driven technology that can accelerate new discoveries.”

Related article

Rare diseases – A cornerstone of big pharma’s commercial offering

NLS asked Nina Rawal, Partner and Co-Head of Ventures at Trill Impact, about her perspective when it comes to financing and supporting rare disease companies. As an investor, what’s your view on rare disease companies and their potential value? “Rare disease is an area that has undergone a minor revolution in recent decades, going from […]

What the award includes

Each awardee receives:

  • A full one-year license for Mavatar Discovery
  • Unlimited access to integrated transcriptomic datasets tailored by disease and tissue type
  • Analytical tools for target discovery, biomarker identification, cross-disease comparison, and hypothesis generation
  • Free onboarding and scientific support from the Mavatar team

Who can apply

The award is open to researchers focusing on areas such as:

  • Genetic and metabolic diseases
  • Immunological and inflammatory conditions
  • Rare cancers and pediatric diseases
  • Other underexplored or low-prevalence disease areas

How to apply

Researchers can express their interest here.